Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib

References

• FerlayJSoerjomataramIErvikM homepage on the InternetGLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11Lyon, FranceInternational Agency for Research on Cancer2013 Available from: http://globocan.iarc.frAccessed February 4, 2017
   Google Scholar
• ChoiYLSodaMYamashitaYEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med2010363181734173920979473
   PubMed Web of Science ®Google Scholar
• GainorJFVargheseAMOuSHALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancerClin Cancer Res201319154273428123729361
   PubMed Web of Science ®Google Scholar
• MorrisSWKirsteinMNValentineMBFusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphomaScience19942635151128112848122112
   PubMed Web of Science ®Google Scholar
• ShawATSolomonBTargeting anaplastic lymphoma kinase in lung cancerClin Cancer Res20111782081208621288922
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med2010363181693170320979469
   PubMed Web of Science ®Google Scholar
• SolomonBJMokTKimDWFirst-line crizotinib versus chemotherapy in ALK-positive lung cancerN Engl J Med2014371232167217725470694
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res20121851472148222235099
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120120ra117
   Web of Science ®Google Scholar
• Van Der SteenNDeschoolmeesterVWoutersALardonFRolfoCPauwelsPAbstract 2593: combination therapy with EGFR-TKI and cMET-TKIs in non-small cell lung cancer: the golden duoCancer Res2015752593
   Google Scholar
• GainorJFOuSHLoganJBorgesLFShawATThe central nervous system as a sanctuary site in ALK-positive non-small-cell lung cancerJ Thorac Oncol20138121570157324389440
   PubMed Web of Science ®Google Scholar
• CostaDBShawATOuSHClinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastasesJ Clin Oncol201533171881188825624436
   PubMed Web of Science ®Google Scholar
• ShawATSpigelDRTanDSMINI01.01: whole body and intracranial efficacy of ceritinib in ALK-inhibitor naive patients with ALK+ NSCLC and brain metastases: results of ASCEND 1 and 3: topic: medical oncologyJ Thorac Oncol20161111SS256
   PubMedGoogle Scholar
• CrinoLAhnMJDe MarinisFMulticenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2J Clin Oncol201634242866287327432917
   PubMed Web of Science ®Google Scholar
• SoriaJCTanDSChiariRFirst-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyLancet20173891007291792928126333
   PubMed Web of Science ®Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutantCancer Cell201119567969021575866
   PubMed Web of Science ®Google Scholar
• LarkinsEBlumenthalGMChenHFDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinibClin Cancer Res201622215171517627413075
   PubMed Web of Science ®Google Scholar
• KodamaTTsukaguchiTYoshidaMKondohOSakamotoHSelective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistanceCancer Lett2014351221522124887559
   PubMed Web of Science ®Google Scholar
• GainorJFDardaeiLYodaSMolecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancerCancer Discov20166101118113327432227
   PubMed Web of Science ®Google Scholar
• KodamaTHasegawaMTakanashiKSakuraiYKondohOSakamotoHAntitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastasesCancer Chemother Pharmacol20147451023102825205428
   PubMed Web of Science ®Google Scholar
• ShawATKimDWNakagawaKCrizotinib versus chemotherapy in advanced ALK-positive lung cancerN Engl J Med2013368252385239423724913
   PubMed Web of Science ®Google Scholar
• SetoTKiuraKNishioMCH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 studyLancet Oncol201314759059823639470
   PubMed Web of Science ®Google Scholar
• TamuraTKiuraKSetoTThree-year follow-up of an alectinib phase I/II study in ALK-positive non-small-cell lung cancer: AF-001JPJ Clin Oncol201735141515152128296581
   PubMed Web of Science ®Google Scholar
• ShawATGandhiLGadgeelSAlectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multi-centre, phase 2 trialLancet Oncol201617223424226708155
   PubMed Web of Science ®Google Scholar
• OuSHAhnJSDe PetrisLAlectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global studyJ Clin Oncol201634766166826598747
   PubMed Web of Science ®Google Scholar
• MullerIBDe LangenAJHoneywellRJGiovannettiEPetersGJOvercoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinibExpert Rev Anticancer Ther201616214715726654422
   PubMed Web of Science ®Google Scholar
• HidaTNokiharaHKondoMAlectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialLancet201739010089293928501140
   PubMed Web of Science ®Google Scholar
• PetersSCamidgeDRShawATAlectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancerN Engl J Med Epub201766
   Web of Science ®Google Scholar
• MarkhamABrigatinib: first global approvalDrugs201777101131113528597393
   PubMed Web of Science ®Google Scholar
• KhozinSBlumenthalGMZhangLFDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancerClin Cancer Res201521112436243925754348
   PubMed Web of Science ®Google Scholar
• FDA Report Alectinib (revision date December 2015)2015 [cited May 24, 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208434s000lbl.pdfAccessed August 12, 2017
   Google Scholar
• HamiltonGRathBBurghuberOPharmacokinetics of crizotinib in NSCLC patientsExpert Opin Drug Metab Toxicol201511583584225732197
   PubMed Web of Science ®Google Scholar
• ShawATFribouletLLeshchinerIResensitization to crizotinib by the lorlatinib ALK resistance mutation L1198FN Engl J Med20163741546126698910
   PubMed Web of Science ®Google Scholar
• KodityalSElvinJASquillaceRA novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinibLung Cancer201692192126775591
   PubMed Web of Science ®Google Scholar
• KatayamaRFribouletLKoikeSTwo novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinibClin Cancer Res201420225686569625228534
   PubMed Web of Science ®Google Scholar
• OuSHGreenboweJKhanZUI1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinibLung Cancer201588223123425736571
   PubMed Web of Science ®Google Scholar
• ToyokawaGInamasuEShimamatsuSIdentification of a novel ALK G1123S mutation in a patient with ALK-rearranged non-small-cell lung cancer exhibiting resistance to ceritinibJ Thorac Oncol2015107e55e5726134233
   PubMed Web of Science ®Google Scholar
• TchekmedyianNAliSMMillerVAHauraEBAcquired ALK L1152R mutation confers resistance to ceritinib and predicts response to alectinibJ Thorac Oncol2016117e87e8827091190
   PubMedGoogle Scholar
• FribouletLLiNKatayamaRThe ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancerCancer Discov20144666267324675041
   PubMed Web of Science ®Google Scholar
• DebruyneDNBhatnagarNSharmaBALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMTOncogene201635283681369126616860
   PubMedGoogle Scholar